KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Efficacy and safety of SKCPT in patients with knee osteoarthritis: A multicenter, randomized, double-blinded, active-controlled phase III clinical trial.J EthnopharmacolPMID 39303963无 PMCID2025-Jan-300.98未发现恶性肿瘤人群证据。待处理
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.N Engl J MedPMID 39555826无 PMCID2025-Jan-300.98未发现恶性肿瘤人群证据。待处理
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.N Engl J MedPMID 39879593PMC76173552025-Jan-300.98未发现恶性肿瘤人群证据。待处理
Unanchored simulated treatment comparison on survival outcomes using parametric and Royston-Parmar models with application to lenvatinib plus pembrolizumab in renal cell carcinoma.BMC Med Res Methodol入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。PMID 39885377PMC117808652025-Jan-300.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Comparison of subconjunctival TRIamcinolone acetonide injection and intravitreal dexamethasone (OZurdex) injection for uveitic and postoperative macular oedema: the TRIOZ study.Br J OphthalmolPMID 39168590无 PMCID2025-Jan-280.98未发现恶性肿瘤人群证据。待处理
HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse: The BEe-HIVe Randomized Clinical Trial.JAMAPMID 39616603PMC116105262025-Jan-280.98未发现恶性肿瘤人群证据。待处理
Early Improvements With Atogepant for the Preventive Treatment of Migraine: Results From 3 Randomized Phase 3 Trials.NeurologyPMID 39715475PMC116685192025-Jan-280.98未发现恶性肿瘤人群证据。待处理
Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple Sclerosis.NeurologyPMID 39960455无 PMCID2025-Jan-280.98未发现恶性肿瘤人群证据。待处理
Treatment of hidradenitis suppurativa with adalimumab in the PIONEER I and II randomized controlled trials reduced indices of systemic inflammation, recognized risk factors for cardiovascular disease.Clin Exp DermatolPMID 39141589无 PMCID2025-Jan-270.98未发现恶性肿瘤人群证据。待处理
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.VaccinePMID 39675209无 PMCID2025-Jan-250.98未发现恶性肿瘤人群证据。待处理
Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39842010无 PMCID2025-Jan-231.00命中用户提供的消化道肿瘤阳性参考集。无 KM 图
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]).Breast Cancer Res疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:非 KM 图;Fig. 3:森林图/亚组分析图。PMID 39849600PMC117617232025-Jan-230.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
The first multiple center prospective study of rhFSH CTP in patients undergoing assisted reproductive technology in China.Sci RepPMID 39837901PMC117511852025-Jan-210.98未发现恶性肿瘤人群证据。待处理
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.J Clin OncolPMID 39250535PMC117713532025-Jan-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.J Clin OncolPMID 39265124PMC117713652025-Jan-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors.J Clin OncolPMID 39411812PMC117713562025-Jan-200.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39798578无 PMCID2025-Jan-181.00命中用户提供的消化道肿瘤阳性参考集。无 KM 图
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.LancetPMID 39798579PMC122826612025-Jan-181.00命中用户提供的消化道肿瘤阳性参考集。已完成
A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial.Clin Cancer ResPMID 39540844PMC117397772025-Jan-170.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial.CNS SpectrPMID 39819527PMC130647062025-Jan-170.98未发现恶性肿瘤人群证据。待处理
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study.BloodPMID 39331724PMC117755072025-Jan-160.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Improving Neck and Jawline Aesthetics With OnabotulinumtoxinA by Minimizing Platysma Muscle Contraction Effects: Efficacy and Safety Results in a Phase 3 Randomized, Placebo-Controlled Study.Aesthet Surg JPMID 39475141PMC117367172025-Jan-160.98未发现恶性肿瘤人群证据。待处理
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39813643无 PMCID2025-Jan-160.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial.Nat Commun疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:森林图/亚组分析图;Fig. 3:森林图/亚组分析图。PMID 39820749PMC117395842025-Jan-160.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Effect of Lemborexant on Daytime Functioning in Adults With Insomnia: Patient-Reported Outcomes From a Phase 3 Clinical Trial.Prim Care Companion CNS DisordPMID 39823487无 PMCID2025-Jan-160.98未发现恶性肿瘤人群证据。待处理
Long-term changes in carotid intima-media thickness according to baseline blood pressure level: J-STARS Echo study.J Neurol SciPMID 39673820无 PMCID2025-Jan-150.98未发现恶性肿瘤人群证据。待处理
Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure.CirculationPMID 39340828PMC117322592025-Jan-140.98未发现恶性肿瘤人群证据。待处理
A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer.Signal Transduct Target TherPMID 39800716PMC117255692025-Jan-130.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Echocardiographic phenotypes of diabetic myocardial disorder: evolution over 15 months follow-up in the ARISE-HF trial.Cardiovasc DiabetolPMID 39806375PMC117305112025-Jan-130.98未发现恶性肿瘤人群证据。待处理
Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies.J Crohns ColitisPMID 39804294PMC117728642025-Jan-110.98未发现恶性肿瘤人群证据。待处理
Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.J Clin OncolPMID 39298738PMC117090012025-Jan-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.J Clin OncolPMID 39303200PMC117090032025-Jan-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Efficacy and Safety of Roxadustat for Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: A Randomized, Open-Label, Active-Controlled Phase III Study.J Clin OncolPMID 39353163PMC117089812025-Jan-100.95The study is a Phase III randomized trial in oncology patients with a drug intervention and reports original results, but it does not have a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP). The primary endpoint is change in hemoglobin concentration, which is a continuous biomarker, not a time-to-event outcome.待处理
Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy.J Clin OncolPMID 39353164PMC117089882025-Jan-100.95The record describes a Phase III randomized trial in oncology (cervical cancer) with original results. However, the intervention is surgical (simple vs. radical hysterectomy), not a drug-containing intervention. The primary and secondary endpoints assessed are sexual health and quality of life (non-time-to-event), not a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS).待处理
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial.Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39389055无 PMCID2025-Jan-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk.N Engl J MedPMID 39225259无 PMCID2025-Jan-090.98未发现恶性肿瘤人群证据。待处理
Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies.BloodPMID 39316653PMC117380362025-Jan-090.60The record is a secondary analysis of two Phase III RCTs with a time-to-event endpoint (EFS). However, the abstract does not establish a drug-containing intervention; it focuses on risk stratification and outcomes of therapy protocols. Without explicit drug vs. non-drug (or standard-of-care) randomized comparison, the drug_intervention criterion cannot be met.待处理
Effect of add-on naldemedine treatment in patients with cancer and opioid-induced constipation insufficiently responding to magnesium oxide: a pooled, subgroup analysis of two randomized controlled trials.Jpn J Clin OncolPMID 39354673PMC117082292025-Jan-080.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Patient experience with eosinophilic esophagitis symptoms and impacts on daily life based on in-trial qualitative interviews.J Patient Rep OutcomesPMID 39777591PMC117115662025-Jan-080.98未发现恶性肿瘤人群证据。待处理
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.Alzheimers Res TherPMID 39780249PMC117080932025-Jan-080.98未发现恶性肿瘤人群证据。待处理
Fatigue After Stroke Educational Recovery Program: A Prospective, Phase III, Randomized Controlled Trial.J Am Heart AssocPMID 39719403PMC120544292025-Jan-070.98未发现恶性肿瘤人群证据。待处理
Challenges in multinational rare disease clinical studies during COVID-19: regulatory assessment of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease.J NeurolPMID 39775064PMC117069032025-Jan-070.98未发现恶性肿瘤人群证据。待处理
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.LancetPMID 39706209无 PMCID2025-Jan-040.98未发现恶性肿瘤人群证据。待处理
Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy.J Antimicrob ChemotherPMID 39556192PMC116959082025-Jan-030.98未发现恶性肿瘤人群证据。待处理
Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial.JNCI Cancer SpectrPMID 39579142PMC117087802025-Jan-030.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Abdominal visceral and subcutaneous adipose tissue associations with postmenopausal breast cancer incidence.JNCI Cancer SpectrPMID 39847539PMC118791262025-Jan-030.90The study is a randomized Phase III trial with a time-to-event endpoint (breast cancer incidence) but lacks a drug-containing intervention; it evaluates associations of body fat distribution with cancer risk, not a therapeutic intervention.待处理
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.N Engl J MedPMID 39213194无 PMCID2025-Jan-020.98未发现恶性肿瘤人群证据。待处理
Asundexian versus Apixaban in Patients with Atrial Fibrillation.N Engl J MedPMID 39225267无 PMCID2025-Jan-020.98未发现恶性肿瘤人群证据。待处理
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.N Engl J MedPMID 39282897PMC120809192025-Jan-020.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。部分完成
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.N Engl J MedPMID 39282902PMC116986432025-Jan-020.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成